![Merck, ABD'deki Pegile İnterferon Alfa-2b Üretimine Son Vermeye Karar Verdi](https://www.klimik.org.tr/wp-content/uploads/2015/09/Merck-ABDdeki-Pegile-İnterferon-Alfa-2b-Üretimine-Son-Vermeye-Karar-Verdi-629x202.jpg)
PEGINTRON (peginterferon alfa-2b) Vials
![FDA logo](https://www.klimik.org.tr/wp-content/uploads/2013/08/FDA-logo.jpg)
Status: Discontinuation
» Therapeutic Categories: Antiviral
Merck Sharp & Dohme Corp. (New 09/24/2015)
Presentation |
Posting Date |
Related Information |
PEGINTRON (peginterferon alfa-2b) injection, 50 mcg per 0.5 mL (NDC 00085-4353-01) | 09/24/2015 | For business reasons, Merck has decided to voluntarily discontinue the manufacture of PEGINTRON vials, Injection, for subcutaneous use, for distribution in the United States, effective date of February 1, 2016. |
PEGINTRON (peginterferon alfa-2b) injection, 80 mcg per 0.5 mL (NDC 00085-4354-01) | 09/24/2015 | For business reasons, Merck has decided to voluntarily discontinue the manufacture of PEGINTRON vials, Injection, for subcutaneous use, for distribution in the United States, effective date of February 1, 2016. |
PEGINTRON (peginterferon alfa-2b) injection, 120 mcg per 0.5 mL (NDC 00085-4355-01) | 09/24/2015 | For business reasons, Merck has decided to voluntarily discontinue the manufacture of PEGINTRON vials, Injection, for subcutaneous use, for distribution in the United States, effective date of February 1, 2016. |
PEGINTRON (peginterferon alfa-2b) injection, 150 mcg per 0.5 mL (NDC 00085-4356-01) | 09/24/2015 | For business reasons, Merck has decided to voluntarily discontinue the manufacture of PEGINTRON vials, Injection, for subcutaneous use, for distribution in the United States, effective date of February 1, 2016. |